Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Phosphatidylserine and DHA on Cognitive Performance in Children With ADHD
Sponsor: Çağlar Charles Daniel Jaicks
Summary
This study aimed to evaluate the effects of different phosphatidylserine (PS) formulations, with or without docosahexaenoic acid (DHA), on cognitive performance in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) or presenting with clinically significant subthreshold ADHD symptoms. A total of 45 medication-naïve children aged 10-14 years were randomly assigned to one of four groups: placebo, PS capsule (PS + DHA), PS sachet (PS without DHA), or PS Plus capsule (higher-dose PS + DHA). The intervention period was eight weeks. Cognitive performance was assessed at baseline and after the intervention using the MOXO continuous performance test and the Stroop test. The study aimed to compare the effects of different PS formulations on attention, impulsivity, hyperactivity, and executive function.
Official title: Differential Cognitive Effects of DHA-Enriched and Standard Phosphatidylserine Formulations in Children With ADHD: A Randomized Placebo-Controlled Trial
Key Details
Gender
All
Age Range
10 Years - 14 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2023-12-30
Completion Date
2025-06-01
Last Updated
2026-04-13
Healthy Volunteers
No
Interventions
Placebo
Placebo formulation identical in appearance and administration to active supplements.
Phosphatidylserine-Omega3
Capsule containing 100 mg phosphatidylserine and 17.78 mg DHA administered once daily for 8 weeks.
Phosphatidylserine-Omega3
Sachet formulation containing 117.78 mg phosphatidylserine without DHA administered once daily for 8 weeks.
DHA Omega-3
Capsule containing 150 mg phosphatidylserine and 26.67 mg DHA administered once daily for 8 weeks.
Locations (1)
Istanbul Aydin University, Department of Child and Adolescent Psychiatry, Istanbul, Turkey
Istanbul, Istanbul, Turkey (Türkiye)